The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Makala, Levi H C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

1 methyl d tryptophan; draining lymph node; Host Immunity; Indoleamine 2,3 dioxygenase; Leishimania major; Leishmaniasis; Mice; plasmacytoid dendritic cell; regulatory T cell

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; LEISHMANIA VACCINE; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CPG ISLAND; DISEASE COURSE; HOST CELL; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION PREVENTION; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MALARIA; MICROENVIRONMENT; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; ANIMAL; ARTICLE; CELLULAR IMMUNITY; CHRONIC DISEASE; DENDRITIC CELL; DISEASE MODEL; HOST PARASITE INTERACTION; IMMUNOLOGY; METABOLISM; MOUSE;

LEISHMANIA MAJOR; MUS;

ANIMALS; CHRONIC DISEASE; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HOST-PARASITE INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LEISHMANIA MAJOR; LEISHMANIASIS; MICE; T-LYMPHOCYTES, REGULATORY;

EID: 84855494867     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-5     Document Type: Review

References (67)

1. "On the possibility of the occurrence of trypanomiasis in India". Leishman WB, The British Medical Journal 1903
2. "Memoranda: On the possibility of the occurence of trypanomiasis in India.". Donovan C, The British Medical Journal 1903
3. "Further notes on Leishman's bodies". Ross R, Ibid 1903 ii 1401
4. Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Peters N, Sacks D, Immunolo Rev 2006 213 159 179 10.1111/j.1600-065X. 2006.00432.x (Pubitemid 44401500)
5. The innate immune response against Leishmania parasites. Liese J, Schleicher U, Bogdan C, Immunobiology 2008 213 377 387 10.1016/j.imbio.2007.12. 005 18406382
6. Immunobiology of leishmaniasis. Sharma U, Singh S, Indian J Exp Biol 2009 47 412 423 19634705
7. Resistance to murine cutaneous leishmaniasis is mediated by TH1 cells, but disease-promoting CD41 cells are different from TH2 cells. Moll H, Rollinghoff M, Eur J Immunol 1990 20 2067 2074 10.1002/eji.1830200927 1976523 (Pubitemid 20355631)
8. Coexistence of antigen-specific TH1 and TH2 cells in genetically susceptible BALB/c mice infected with Leishmania major. Lohoff M, Sommer F, Solbach W, Rollinghoff M, Immunobiology 1989 179 412 421 10.1016/S0171-2985(89) 80045-2 2575598 (Pubitemid 19268315)
9. Induction of Th1 and Th2 CD41 subsets during murine Leishmania major infection. Locksley RM, Heinzel FP, Holaday BJ, Mutha SS, Reiner SL, Sadick MD, Res Immunol 1991 142 28 32 10.1016/0923-2494(91)90007-6 1829257
10. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. Scott P, J Immunol 1991 147 3149 55 1833466
11. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A, J Exp Med 1988 168 1675 84 10.1084/jem.168.5.1675 2903212 (Pubitemid 19023255)
12. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. Holaday BJ, Sadick MD, Wang ZE, Reiner SL, Heinzel FP, Parslow TG, Locksley RM, J Immunol 1991 147 1653 8 1831830
13. The regulation of immunity to Leishmania major. Reiner SL, Locksley RM, Annu Rev Immunol 1995 13 151 77 10.1146/annurev.iy.13.040195.001055 7612219
14. Infected site-restricted Foxp31 natural regulatory T cells are specific for microbial antigens. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y, J Exp Med 2006 203 777 88 10.1084/jem.20052056 16533885
15. Regulatory T cells in the control of hostmicroorganism interactions (*). Belkaid Y, Tarbell K, Annu Rev Immunol 2009 27 551 89 10.1146/annurev.immunol.021908.132723 19302048
16. Arming Treg cells at the inflammatory site. Belkaid Y, Tarbell KV, Immunity 2009 30 322 3 10.1016/j.immuni.2009.03.004 19303386
17. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ, International Journal of Cancer 2002 101 151 155 10.1002/ijc.10645 (Pubitemid 34970907)
18. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. Munn DH, Sharma MD, Hou D, Baban B, Lee J, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL, J Clin Invest 2004 114 280 290 15254595 (Pubitemid 39071633)
19. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y, Blood 2005 106 2382 2390 10.1182/blood-2005-04-1403 15961516 (Pubitemid 41510811)
20. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. Munn DH, Mellor AL, J Clin Invest 2007 117 1147 1154 10.1172/JCI31178 17476344 (Pubitemid 46718399)
21. How do Protozoan Parasites Survive inside Macrophages? Bogdan C, Röllinghoff M, Parasitology Today 1999 15 1 22 28 10.1016/S0169-4758(98) 01362-3 10234174 (Pubitemid 29246041)
22. Leishmania major Attenuates Host Immunity by Stimulating Local Indoleamine 2,3-Dioxygenase Expression. Makala LH, Baban B, Lemos H, El-Awady AR, Chandler PR, Hou DY, Munn DH, Mellor AL, J Infect Dis 2011 203 715 25 10.1093/infdis/jiq095 21282196
23. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Mellor AL, Munn DH, Immunol Today 1999 20 469 473 10.1016/S0167-5699(99)01520-0 10500295 (Pubitemid 29476077)
24. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y, Proc Natl Acad Sci USA 2006 103 2611 2616 10.1073/pnas.0508996103 16477023
25. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. Taylor MW, Feng GS, FASEB J 1991 5 2516 2522 1907934 (Pubitemid 21905800)
26. Prevention of allogeneic fetal rejection by tryptophan catabolism. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL, Science 1998 281 1191 1193 9712583 (Pubitemid 28406294)
27. IDO expression in dendritic cells: Tolerance and tryptophan catabolism. Mellor AL, Munn DH, Nat Rev Immunol 2004 4 762 774 10.1038/nri1457 15459668 (Pubitemid 39336293)
28. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ, International Journal of Cancer 2002 101 151 155 10.1002/ijc.10645 (Pubitemid 34970907)
29. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. Munn DH, Sharma MD, Hou D, Baban B, Lee J, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL, J Clin Invest 2004 114 280 290 15254595 (Pubitemid 39071633)
30. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y, Blood 2005 106 2382 2390 10.1182/blood-2005-04-1403 15961516 (Pubitemid 41510811)
31. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. Munn DH, Mellor AL, J Clin Invest 2007 117 1147 1154 10.1172/JCI31178 17476344 (Pubitemid 46718399)
32. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL, Immunity 2005 22 633 642 10.1016/j.immuni.2005.03.013 15894280 (Pubitemid 40719198)
33. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH, Blood 2009 113 6102 6111 10.1182/blood-2008-12-195354 19366986
34. Creating immune privilege: active local suppression that benefits friends, but protects foes. Mellor AL, Munn DH, Nat Rev Immunol 2008 8 74 80 10.1038/nri2233 18064049
35. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwashima M, Munn DH, J Immunol 2003 171 1652 1655 12902462 (Pubitemid 36966447)
36. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Mellor AL, Chandler PR, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold SP, Adams E, Munn DH, Int Immunol 2004 16 1391 1401 10.1093/intimm/dxh140 15351783 (Pubitemid 39341552)
37. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman A, Kahler DJ, Munn DH, Mellor AL, Int Immunol 2005 17 909 919 10.1093/intimm/dxh271 15967784 (Pubitemid 41417958)
38. Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH, J Immunol 2005 175 5601 5605 16237046 (Pubitemid 41508038)
39. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL, Mellor AL, Science 2002 297 1867 1870 10.1126/science.1073514 12228717 (Pubitemid 35024345)
40. GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-Dioxygenase. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL, Immunity 2005 22 1 10 10.1016/j.immuni.2005.01.001 (Pubitemid 40143444)
41. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, Barr IG, Doherty PC, Godfrey DI, Turner SJ, Proc Natl Acad Sci USA 2009 106 3330 3335 10.1073/pnas.0813309106 19211791
42. Relationship between interferon-g, indoleamine 2,3-dioxygenase, and tryptophan catabolism. Taylor MW, Feng G, FASEB Journal 1991 5 2516 2522 1907934 (Pubitemid 21905800)
43. Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y, J Exp Med 2006 203 777 788 10.1084/jem.20052056 16533885
44. Natural regulatory T cells and parasites: a common quest for host homeostasis. Belkaid Y, Blank RB, Suffia I, Immunol Rev 2006 212 287 300 10.1111/j.0105-2896.2006.00409.x 16903921 (Pubitemid 44116715)
45. Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells. Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, Belkaid Y, Sacks DL, Infect Immun 2005 73 6620 6628 10.1128/IAI.73.10.6620-6628.2005 16177338 (Pubitemid 41372127)
46. Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. Qi H, Ji J, Wanasen N, Soong L, Infect Immun 2004 72 988 995 10.1128/IAI.72.2.988-995.2004 14742545 (Pubitemid 38166680)
47. Programme for the surveillance and control of leishmaniasis. WHO, 2001 http://www.who.int/emc/diseases/leish/leishmaniasis.pdf. (Internet publication)
48. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL, J Immunol 2009 183 2475 2483 10.4049/jimmunol.0900986 19635913
49. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes activate mature Tregs via indoleamine 2,3-dioxygenase. Sharma MD, Baban B, Chandler PR, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH, J Clin Invest 2007 117 1 13
50. Regulatory T cell lineage specification by the forkhead transcriptionfactor foxp3. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY, Immunity 2005 22 329 341 10.1016/j.immuni.2005.01.016 15780990 (Pubitemid 40387475)
51. HIV vaccine failure prompts Merck to halt trial. Nature 2007 449 390 17898737
52. Failure of the Merck HIV vaccine: an uncertain step forward. Robb ML, Lancet 2008 372 1857 1858 10.1016/S0140-6736(08)61593-7 19012958
53. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC, Nat Med 2008 14 617 621 10.1038/nm.f.1759 18535579 (Pubitemid 351809543)
54. Creating immune privilege: active local suppression that benefits friends, but protects foes. Mellor AL, Munn DH, Nat Rev Immunol 2008 8 74 80 10.1038/nri2233 18064049
55. Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Peters N, Sacks D, Immunol Rev 2006 213 159 179 10.1111/j.1600-065X. 2006.00432.x 16972903 (Pubitemid 44401500)
56. Interleukin-10 production by effector T cells: Th1 cells show self control. Trinchieri G, J Exp Med 2007 204 239 243 10.1084/jem.20070104 17296790 (Pubitemid 46294539)
57. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, Sacks DL, J Exp Med 2001 194 1497 1506 10.1084/jem.194.10.1497 11714756 (Pubitemid 33081524)
58. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Mellor AL, Munn DH, Nat Rev Immunol 2004 4 762 774 10.1038/nri1457 15459668 (Pubitemid 39336293)
59. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH, Int Immunol 2004 16 1391 1401 10.1093/intimm/dxh140 15351783 (Pubitemid 39341552)
60. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, L Mellor A, J Clin Invest 2004 114 280 290 15254595 (Pubitemid 39071633)
61. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman A, Kahler DJ, Munn DH, Mellor AL, Int Immunol 2005 17 909 919 10.1093/intimm/dxh271 15967784 (Pubitemid 41417958)
62. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH, Cancer Res 2007 67 792 801 10.1158/0008-5472.CAN-06- 2925 17234791 (Pubitemid 46192220)
63. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC, Nat Med 2005 11 312 319 10.1038/nm1196 15711557 (Pubitemid 40460560)
64. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL, Proc Natl Acad Sci USA 2008 105 17073 17078 10.1073/pnas.0806173105 18952840
65. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH, J Clin Invest 2007 117 2570 2582 10.1172/JCI31911 17710230 (Pubitemid 47494358)
66. A potential role of indoleamine 2,3-dioxygenase-specific T cells in leishmania vaccination. (Comment on J Infect Dis. 2011 Mar 1;203(5):715-25). Andersen MH, J Infect Dis 2011 204 488 489 10.1093/infdis/jir274 21742850
67. The first drug for leishmaniasis treatment. No Authors, IJMR 1922 10 492